Marken adding nursing network for at-home clinical trials

By Melissa Fassbender contact

- Last updated on GMT

(Image: Getty/Halfpoint)
(Image: Getty/Halfpoint)
Marken is planning to develop a global home-based nursing network as an increasing amount of clinical trial protocols now include a DTP/DFP component.

Marken currently offers its Direct to/from Patient (DTP/DFP) services in 51 countries. The new nursing services will enable the company to collect a patient’s biological samples in their home and in accordance with clinical protocols.

Services will potentially include intravenous infusion, blood draws including safety lab samples, biologic sampling, such as pharyngeal and oral mucosal swabs, in addition to clinical assessment of vital signs and other mobile-based electronic data collection, according to the company.

Additionally, nurses and patients in the US are able to drop off biological samples at any one of 4,600 The UPS Store locations​.

The number of nurses contracted to work with Marken will depend on patient locations, protocol design, number of patients, and the countries in which the trial will take place, explained Christine Noble, senior director, global marketing, Marken.

“We expect that the Marken nursing network will grow rapidly and exponentially in response to the increasing number of trial protocols which are already including DTP/DFP for patients,”​ Noble added. “This new service will offer more options for patients and sponsors.”

The network will be available to countries where regulators permit DTP and DFP services for patients enrolled in clinical trials, Noble explained, and for a trial in which sponsors have added a DTP/DPF component to the trial protocol.

“Many times, the indication for the trial can drive the need for a DTP/DFP component,”​ she added

Marken continues to experience growth across Asia, Noble said, and more trials are underway in Russia, Ukraine, Israel, and several other countries in the Middle East.

“As more and more countries recognize the need, we expect that the number of countries in which the service can be offered will continue to increase,” ​she added.

Wes Wheeler, Marken CEO, noted in the release that “24% of pharmaceutical companies are moving to virtual or partially virtual trials and another 33% are expected to start ‘siteless’ trials in the near future.” 

“We expect this trend will continue to place a heavy demand for our services,” ​he said.

Related news

Show more

Related products

show more

Laboratory Solutions for COVID-19 Clinical Trials

Laboratory Solutions for COVID-19 Clinical Trials

Q2 Solutions | 10-Jun-2020 | Clinical Study

As a leading laboratory services organization for trials across the globe, we are proud to partner with clients to support COVID-19 clinical trials. Our...

Parents as Gatekeepers for Children with Cancer

Parents as Gatekeepers for Children with Cancer

PRA Health Sciences | 08-Jun-2020 | Technical / White Paper

The RACE for Children Act will require new drugs intended for adult cancer treatment to also be studied in pediatric cancers when the molecular target...

RACE Act Prompts Pediatric Oncology Trials

RACE Act Prompts Pediatric Oncology Trials

PRA Health Sciences | 04-May-2020 | Technical / White Paper

Many providers prescribe drugs off-label to pediatric patients, even though there have been few pediatric trials for many of these drugs. In response,...

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 01-Mar-2020 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

Related suppliers

Follow us


View more